X4 Pharmaceuticals (XFOR) Cash from Operations (2017 - 2025)

X4 Pharmaceuticals has reported Cash from Operations for 9 years, with the latest figure at 15509000.0 in Q4 2025.

• For the quarter ending Q4 2025, Cash from Operations rose 53.0% year-over-year to 15509000.0; the trailing twelve-month figure through Dec 2025 stood at 85600000.0 (up 47.97% YoY), and the FY2025 full-year result was 85600000.0, up 34.61% from the prior year.
• Cash from Operations for Q4 2025 stood at 15509000.0, up from 27791000.0 in the prior quarter.
• The five-year high for Cash from Operations was 12400000.0 in Q1 2025, with the low at 68800000.0 in Q3 2023.
• Historically, Cash from Operations has averaged 28454500.0 across 5 years, with a median of 23370500.0 in 2022.
• Annual changes were most pronounced in 2023 — Cash from Operations sank 256.37% — and 2025, when it soared 63.09%.
• X4 Pharmaceuticals' Cash from Operations stood at 19053000.0 in 2021, then slipped by 0.21% to 19093000.0 in 2022, then sank by 45.33% to 27747000.0 in 2023, then decreased by 18.91% to 32995000.0 in 2024, then jumped by 53.0% to 15509000.0 in 2025.
• The last three Cash from Operations figures came in at 15509000.0 (Q4 2025), 27791000.0 (Q3 2025), and 29900000.0 (Q2 2025), per Business Quant data.